• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

作者信息

Peled Nir, Palmer Gary, Hirsch Fred R, Wynes Murry W, Ilouze Maya, Varella-Garcia Marileila, Soussan-Gutman Lior, Otto Geoff A, Stephens Philip J, Ross Jeffrey S, Cronin Maureen T, Lipson Doron, Miller Vincent A

机构信息

The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

出版信息

J Thorac Oncol. 2012 Sep;7(9):e14-6. doi: 10.1097/JTO.0b013e3182614ab5.

DOI:10.1097/JTO.0b013e3182614ab5
PMID:22895149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3645938/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3d/3645938/fbcfd8eee215/nihms460575f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3d/3645938/dbc3beac31e1/nihms460575f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3d/3645938/c50e4f556e0c/nihms460575f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3d/3645938/fbcfd8eee215/nihms460575f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3d/3645938/dbc3beac31e1/nihms460575f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3d/3645938/c50e4f556e0c/nihms460575f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3d/3645938/fbcfd8eee215/nihms460575f3.jpg

相似文献

1
Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.新一代测序鉴定出，免疫组化证实一名转移性非小细胞肺癌患者存在一种新的对克唑替尼敏感的间变性淋巴瘤激酶（ALK）重排。
J Thorac Oncol. 2012 Sep;7(9):e14-6. doi: 10.1097/JTO.0b013e3182614ab5.
2
Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.非小细胞肺癌中具有克唑替尼敏感性ALK重排的非典型阴性ALK断裂分离荧光原位杂交检测结果
J Thorac Oncol. 2014 Mar;9(3):e21-3. doi: 10.1097/JTO.0000000000000013.
3
ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.肺腺癌中ALK荧光原位杂交（FISH）模式及通过下一代测序检测ALK融合
Oncotarget. 2016 Dec 13;7(50):82943-82952. doi: 10.18632/oncotarget.12705.
4
Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.克唑替尼在一名ALK免疫组化阳性/荧光原位杂交阴性转移性肺腺癌患者中的疗效。
Lung Cancer. 2016 Aug;98:118-121. doi: 10.1016/j.lungcan.2016.06.001. Epub 2016 Jun 3.
5
Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.克唑替尼治疗的非小细胞肺癌患者组织中间变性淋巴瘤激酶蛋白表达的定量分析
Clin Chem. 2016 Jan;62(1):252-61. doi: 10.1373/clinchem.2015.245860. Epub 2015 Nov 19.
6
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.下一代测序揭示了一种新型 NSCLC ALK F1174V 突变，并证实 ALK G1202R 突变使对克唑替尼治疗后进展的 ALK 重排 NSCLC 患者对艾乐替尼（CH5424802/RO5424802）具有高水平耐药性。
J Thorac Oncol. 2014 Apr;9(4):549-53. doi: 10.1097/JTO.0000000000000094.
7
Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.克唑替尼和阿来替尼序贯治疗ALK重排阳性非小细胞肺癌患者的无进展生存期和总生存期
Clin Lung Cancer. 2016 Nov;17(6):528-534. doi: 10.1016/j.cllc.2016.05.001. Epub 2016 May 18.
8
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.塞瑞替尼与化疗用于既往接受过化疗和克唑替尼治疗的间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌患者（ASCEND-5）：一项随机、对照、开放标签、III 期临床试验。
Lancet Oncol. 2017 Jul;18(7):874-886. doi: 10.1016/S1470-2045(17)30339-X. Epub 2017 Jun 9.
9
Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.对免疫组织化学（IHC）呈阳性且荧光原位杂交（FISH）呈阴性的ALK阳性肺腺癌患者使用克唑替尼的反应。
Oncotarget. 2016 Sep 27;7(39):64410-64420. doi: 10.18632/oncotarget.10560.
10
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.ALK重排的晚期非小细胞肺癌（NSCLC）对克唑替尼的耐药性：机制、治疗策略及新的靶向治疗方法
Curr Clin Pharmacol. 2016;11(2):77-87. doi: 10.2174/1574884711666160502124134.

引用本文的文献

1
Discordant Status in Non-Small Cell Lung Carcinoma: A Detailed Reevaluation Comparing IHC, FISH, and NGS Analyses.非小细胞肺癌中的不一致状态：免疫组化、FISH 和 NGS 分析的详细比较
Int J Mol Sci. 2024 Jul 26;25(15):8168. doi: 10.3390/ijms25158168.
2
Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.TFG-ROS1 融合基因鉴定后 spindle 细胞肉瘤的重新分类：一项展示下一代测序在肉瘤中临床获益的病例。
Mol Genet Genomic Med. 2024 Apr;12(4):e2423. doi: 10.1002/mgg3.2423.
3
Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.免疫组织化学与二代测序检测ALK融合基因重排结果的一致性
Int J Clin Oncol. 2024 Feb;29(2):96-102. doi: 10.1007/s10147-023-02451-6. Epub 2024 Jan 6.
4
SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report.一名对ALK抑制剂治疗反应良好的肺腺癌患者中的SDK1-ALK融合：病例报告
Front Oncol. 2022 Mar 4;12:860060. doi: 10.3389/fonc.2022.860060. eCollection 2022.
5
High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare fusion sites: a case report.阿来替尼对一名具有两个罕见融合位点的晚期肺腺癌患者疗效显著：一例报告
Transl Lung Cancer Res. 2022 Jan;11(1):100-110. doi: 10.21037/tlcr-21-1039.
6
Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.涎腺分泌型癌中存在一种不常见但具有高度显著意义的 ETV6-NTRK3 重排的 FISH 信号模式的特征：病例报告。
Diagn Pathol. 2021 Aug 9;16(1):73. doi: 10.1186/s13000-021-01133-z.
7
Comparison of Clinical Efficacy of Alectinib Crizotinib in -Positive Non-Small Cell Lung Cancer: A Meta-Analysis.阿来替尼与克唑替尼治疗ALK阳性非小细胞肺癌的临床疗效比较：一项荟萃分析。
Front Oncol. 2021 Jun 2;11:646526. doi: 10.3389/fonc.2021.646526. eCollection 2021.
8
Quantitative Multiplexed Proteomics Could Assist Therapeutic Decision Making in Non-Small Cell Lung Cancer Patients with Ambiguous ALK Test Results.定量多重蛋白质组学可协助ALK检测结果不明确的非小细胞肺癌患者进行治疗决策。
Cancers (Basel). 2021 May 12;13(10):2337. doi: 10.3390/cancers13102337.
9
Molecular diagnosis in non-small-cell lung cancer: expert opinion on and testing.非小细胞肺癌的分子诊断：专家意见与 和 检测。
J Clin Pathol. 2022 Mar;75(3):145-153. doi: 10.1136/jclinpath-2021-207490. Epub 2021 Apr 19.
10
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the Gene Have Durable Responses to ALK Kinase Inhibitors.
Lung Cancer (Auckl). 2020 Apr 17;11:33-39. doi: 10.2147/LCTT.S239675. eCollection 2020.

本文引用的文献

1
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.间变性淋巴瘤激酶抑制在非小细胞肺癌中的作用。
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
2
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.携带EML4-ALK的非小细胞肺癌患者的临床特征及预后
J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.
3
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.磷酸酪氨酸信号的全球调查确定了肺癌中的致癌激酶。
Cell. 2007 Dec 14;131(6):1190-203. doi: 10.1016/j.cell.2007.11.025.